A&M Perspectives: How asset light pharmaceutical companies can augment value creation in a disrupted market environment
Over the past two decades, originator pharmaceutical businesses have increasingly disposed of late-stage drug portfolios to third parties. This has spurred the growth of asset-light pharmaceutical companies with radically different operating models. Operating through networks of Contract Development and Manufacturing Organisations (CDMOs), these businesses avoid major capital expenditure, have greater flexibility, and can therefore focus on critical capabilities such as supply chain excellence, market authorisation and technical transfers.
While there are advantages, asset-light models are complex. Many different partners are involved, comprising of specialised CDMOs, distribution partners and a mix of in-house sales and country distributors. This leads to challenges related to demand planning, inventory control and cost control.
At the same time, asset-light pharma businesses are having to respond to global challenges including rising inflation, supply chain disruptions, Covid-19 outbreaks and growing geopolitical tensions.
Based on our experiences of delivering change for a range of asset-light pharmaceutical companies across Europe, we recommend five levers of value creation.
Five value levers for asset-light pharmaceutical businesses
- CDMO rationalisation and technical transfer excellence
- S&OP/ IBP upgrades
- Inventory and working capital optimisation
- Logistics simplification
- Digital tools deployment (commercial focus)
Download
Related Insights
Shocks to global supply chains are increasing in frequency and severity. Russia’s invasion of Ukraine, new Covid outbreaks in China and rising interest rates in the US are occurring at once with ramifications for global trade. What steps can companies take to improve supply chain resilience.
Alvarez & Marsal Expands Infrastructure & Capital Projects Offering Into Canada With The Integration of LQ Consulting And Management
February 9, 2026
Leading global professional services firm Alvarez & Marsal (A&M) announced the integration of LQ Consulting and Management with A&M’s INFRA practice in Canada and appointed Pierre Légaré as Managing Director and Leader of INFRA Canada along with Senior Directors Arshya Qureshi and Gordon Lung.
Virtual Care: Evolving Reimbursement Laws and Strategies for Driving New Revenue Streams
December 3, 2024
Virtual care is transforming healthcare—making it more accessible, efficient, and cost-effective. In A&M Healthcare Industry Group’s latest podcast, we delve into the evolving reimbursement laws and strategies for generating new revenue streams.
Ballad Health is Working to Reduce 100,000 Years of Potential Life Lost
November 20, 2024
Working to reduce 100,000 years of potential life in the communities he serves is just one of the Moonshots that Tony Keck, Executive Vice President for System Innovation and Chief Population Health Officer at Ballad Health is working toward achieving.
Dr. Place is Leading Avera McKennan Hospital & University Health Center to Ensure Its Rural Communities Receive the Same Quality of Care as Urban Areas
October 16, 2024
As President and CEO of Avera McKennan Hospital & University Health Center, Ronald Place, M.D., is committed to ensuring the same level of quality care is delivered to his rural community as in urban areas.
